Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss
Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Lowers Price Target to $53
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals with a Overweight and lowers the price target from $57 to $53.
Positive Outlook for Mirum Pharmaceuticals With Buy Rating Amid Upcoming Catalysts and Robust Financials
Mirum Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Mirum Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Express News | Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $38
Mirum Pharmaceuticals Price Target Maintained With a $40.00/Share by Cantor Fitzgerald
Mirum Pharmaceuticals Price Target Maintained With a $40.00/Share by Cantor Fitzgerald
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Express News | Mirum Pharmaceuticals Inc : Raymond James Cuts Target Price to $60 From $63
Express News | HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $58 Price Target
Mirum Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 131.63% HC Wainwright & Co. → $58 Reiterates Buy → Buy 04/17/2024 91.69% Stifel → $48 Initiates
Express News | Mirum Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $42 From $43
Mirum Pharmaceuticals Q1 2024 GAAP EPS $(0.54) Misses $(0.48) Estimate, Sales $69.222M Miss $70.171M Estimate
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 32.5 percent increase over losses o
Mirum Pharmaceuticals | 10-Q: Quarterly report
Mirum Pharmaceuticals: Volixibat VISTAS and VANTAGE Interim Analyses Scheduled for June
Mirum Pharmaceuticals: Volixibat VISTAS and VANTAGE Interim Analyses Scheduled for June
Mirum Pharmaceuticals Sees FY Rev $310M-$320M >MIRM
Mirum Pharmaceuticals Sees FY Rev $310M-$320M >MIRM
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q1 Revenue $69.2M, Vs. Street Est of $70.2M
04:04 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q1 Revenue $69.2M, vs. Street Est of $70.2M
Express News | Mirum Pharmaceuticals Inc: Cash Balance of $302.8 Mln as of March 31, 2024
Express News | Mirum Pharmaceuticals Inc: Q1 2024 Total Revenue of $69.2 Mln, on Track to Achieve Full-Year Guidance of $310 to $320 Mln
No Data